Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Chaithanya Ganji; Batoul Farran

doi:10.1016/j.drudis.2021.12.013

Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Chaithanya Ganji, Batoul Farran

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.

Original language	English (US)
Pages (from-to)	1404-1410
Number of pages	7
Journal	Drug Discovery Today
Volume	27
Issue number	5
DOIs	https://doi.org/10.1016/j.drudis.2021.12.013
State	Published - May 2022
Externally published	Yes

Keywords

DNA methylation
DNMTi
Epigenetics
HDACi
Histone acetylation
Pancreatic cancer

ASJC Scopus subject areas

Pharmacology
Drug Discovery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.drudis.2021.12.013

Cite this

@article{29f488f0d4614acfb21750394e8827ad,

title = "Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy",

abstract = "Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.",

keywords = "DNA methylation, DNMTi, Epigenetics, HDACi, Histone acetylation, Pancreatic cancer",

author = "Chaithanya Ganji and Batoul Farran",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Ltd",

year = "2022",

month = may,

doi = "10.1016/j.drudis.2021.12.013",

language = "English (US)",

volume = "27",

pages = "1404--1410",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Limited",

number = "5",

}

TY - JOUR

T1 - Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

AU - Ganji, Chaithanya

AU - Farran, Batoul

PY - 2022/5

Y1 - 2022/5

N2 - Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.

AB - Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.

KW - DNA methylation

KW - DNMTi

KW - Epigenetics

KW - HDACi

KW - Histone acetylation

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85122798858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122798858&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2021.12.013

DO - 10.1016/j.drudis.2021.12.013

M3 - Review article

C2 - 34952224

AN - SCOPUS:85122798858

SN - 1359-6446

VL - 27

SP - 1404

EP - 1410

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 5

ER -

Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this